A bovine adenovirus vaccine for broad protection against seasonal and pandemic flu
Adenoviral Vector-based Pandemic Influenza Vaccine
This project is developing a bovine adenovirus-based vaccine designed to protect people from seasonal influenza and potential pandemic avian flu strains.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-11326214 on NIH RePORTER |
What this research studies
Researchers use a harmless bovine adenovirus (BAd3) as a delivery platform to present flu proteins to the immune system, aiming for protection across multiple influenza strains. They add a short autophagy-inducing peptide (AIP-C5) to boost T cell responses and strengthen immune memory. In mice the platform produced higher antigen expression and stronger innate and adaptive responses than common human adenovirus vectors and is not affected by existing human adenovirus immunity. The team aims to move from animal studies toward clinical testing to determine if this approach protects people against seasonal and avian influenza.
Who could benefit from this research
Good fit: Likely candidates for future trials would be adults at risk of influenza exposure, such as healthcare workers, older adults, and people in regions with avian flu outbreaks.
Not a fit: People who are severely immunocompromised, have known allergies to vaccine components, or who cannot or do not want to join clinical trials may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this could lead to a broadly protective flu vaccine that covers seasonal and potential pandemic strains while needing lower doses.
How similar studies have performed: Adenovirus-based influenza vaccines have shown promise in animals and some human trials, but combining a bovine Ad3 platform with an autophagy-inducing peptide is relatively novel.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Mittal, Suresh K — Purdue University
- Study coordinator: Mittal, Suresh K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.